Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2013 Results
Date:5/9/2013

e on the SEC's website at www.sec.gov.  In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results.  There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda.  Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein.  Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf.  The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. VANDA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)Three Months EndedMarch 31March 31(in thousands, except for share and per share amounts)

20132012Revenues:Licensing agreement

$

6,606$

6,606Royalty revenue1,4621,535Total revenues8,0688,141Operating expenses:Research and development7,96012,180General and administrative3,9583,909Intangible asset amortization369369Total operating expenses12,28716,458Loss from operations(4,219)(8,317)Other income46355Loss before tax benefit(4,173)(7,962)Tax benefit--Net loss

$

(4,173)$

(7,962)Net loss per share:Basic

$

(0.15)$

(0.28)Diluted

$

(
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
2. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
3. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
4. Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
5. Adamis Pharmaceuticals CEO Provides Update for Shareholders
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
8. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
9. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
10. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
11. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 The report ... Dispensing Systems, Packaging and Labeling Systems, Table-top Counters) ... - Global Forecasts & Trends to 2019” analyzes ... opportunities in North America, Europe, Asia-Pacific, and the ... market tables and 30 figures spread through 300 ...
(Date:10/20/2014)... Convey Computer , the leader in ... State University won first place in the 2014 ... the team’s solution achieved the highest overall performance in ... place finisher. , Experts from all segments of the ... challenge, using a variety of design tools, hardware and ...
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... million which brings Q3 orders to $5.8 million and provides a ... projects in North America and one in ... to bid new projects at record levels," said Peter Bruijns ... higher at the end of Q3 than they have been for ...
(Date:10/20/2014)... 2014  GenVec, Inc. (NASDAQ: GNVC ) today ... from its board of directors effective on October 24, 2014.  ... served as its chairman from June 2006 to November 2013.  ... Corporate Governance and Audit Committees of the board.  ... of dedicated service to GenVec, and its stockholders," said ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2
... July 8 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics,Inc. (OTC Bulletin ... firm specializing in the manufacture, research, development,marketing ... Dr.,Shuguang Fang, China-Biotics, Chief Technology Officer, has ... China,s 3rd Annual Food Safety Technology Forum,2008 ...
... purchase, distribute US-made bulk API, BATON ... Albemarle Corporation (NYSE: ALB ), a ... and other active pharmaceutical,ingredients (APIs), has signed ... Laboratories Ltd. As per the agreement, effective,immediately, ...
... Board and Management Focused on Near-Term Milestones and Maintain ... ... DIEGO, July 8 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI, OTC: MGIFF), ... requisition for a special meeting of shareholders,for the purpose of ...
Cached Biology Technology:China-Biotics, Inc. to Present at China's 3rd Annual Food Safety Technology Forum 2008 2China-Biotics, Inc. to Present at China's 3rd Annual Food Safety Technology Forum 2008 3Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 3MIGENIX Corporate Update and Requisition of Special Meeting 2MIGENIX Corporate Update and Requisition of Special Meeting 3MIGENIX Corporate Update and Requisition of Special Meeting 4MIGENIX Corporate Update and Requisition of Special Meeting 5MIGENIX Corporate Update and Requisition of Special Meeting 6MIGENIX Corporate Update and Requisition of Special Meeting 7MIGENIX Corporate Update and Requisition of Special Meeting 8
(Date:10/18/2014)... for evaluation of suspected genetic conditions, whole-exome sequencing ... including detection of a number of rare genetic ... to a study appearing in JAMA . ... the American Society of Human Genetics annual meeting. ... regions of thousands of genes simultaneously using next-generation ...
(Date:10/17/2014)... German . To ... treating overdoses, doctors are often limited to supportive therapy such ... a combination of drugs involved. So what can be done ... pills? ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical ... this question. "The task was to develop an agent that ...
(Date:10/16/2014)... they are anything but sustainable: environmental damage to ... becoming increasingly evident. Despite their disadvantages, however, monocultures ... as the sole possibility of achieving higher yields ... Schmid, an ecology professor at the University of ... and forestry. After all, a new study carried ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... the possibility that the critically short supply of livers ... "marginal" livers with a substance that protects them from ... report appears in ACS, journal Molecular Pharmaceutics . ... for liver transplants has grown over the years, though ...
... DALLAS June 1, 2011 A drug ... as a therapy for a common form of dementia, ... hydroxamic acid (SAHA) holds promise as a first-generation drug ... (FTD), a progressive, inherited neurodegenerative disease for which there ...
... Virginia Tech,s Advanced Experimental Thermofluid Engineering Research ... professor Pavlos P. Vlachos, professor of mechanical engineering, ... mechanics from the Measurement Science and Technology ... Physics. John J. Charonko, of Blacksburg, ...
Cached Biology News:Cancer drug holds promise as first treatment for common, inherited dementia 2Virginia Tech mechanical engineers win measurement science best paper award 2
...
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
... Resistant (X/R) Red System consists of ... Activator and X/R Red Buffer. The ... phosphatase to produce red staining that ... Contains:, , Buffer, 100 mL , ...
Human Cell Line Slides...
Biology Products: